U.S. Markets open in 1 hr 16 mins

How Did Amarin’s Vascepa Perform in Fiscal 2019?

Margaret Patrick
How Did Amarin’s Vascepa Perform in Fiscal 2019?

Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?(Continued from Prior Part)Vascepa demand in the first quarterIn the first quarter, Amarin (AMRN) reported net product sales of $72.7 million, a YoY rise of 66%. According to